The NLRP3 inflammasome, a caspase-1 activation platform, plays a key role in the modulation of liver inflammation and fibrosis. Here, we tested the hypothesis that interleukin 17 (IL-17) and tumor necrosis factor (TNF) are key cytokines involved in amplifying and perpetuating the liver damage and fibrosis resulting from NLRP3 activation. To address this hypothesis, gain-of-function Nlrp3 A350V knock-in mice were bred onto il17a and Tnf knockout backgrounds allowing for constitutive Nlrp3 activation in myeloid derived cells in mice deficient in IL-17 or TNF. Livers of Nlrp3 A350V knock-in mice exhibited severe liver inflammatory changes characterized by infiltration with neutrophils, increased expression of chemokine (C-X-C motif) ligand (CXCL) 1 and CXCL2 chemokines, activated inflammatory macrophages, and elevated levels of IL-17 and TNF. Mutants with ablation of il17a signal showed fewer neutrophils when compared to intact Nlrp3 A350V mutants, but still significant inflammatory changes when compared to the nonmutant il17a knockout littermates. The severe inflammatory changes associated with mutant Nlrp3 were almost completely rescued by Tnf knockout in association with a marked decrease in circulating IL-1b levels. Intact Nlrp3 A350V mutants showed changes in liver fibrosis, as evidenced by morphometric quantitation of Sirius Red staining and increased mRNA levels of profibrotic genes, including connective tissue growth factor and tissue inhibitor of matrix metalloproteinase 1. Il17a lacking mutants exhibited amelioration of the aforementioned fibrosis, whereas Tnf-deficient mutants showed no signs of fibrosis when compared to littermate controls. Conclusion: Our study uncovers key roles for TNF and, to a lesser extent, IL-17 as mediators of liver inflammation and fibrosis induced by constitutive NLRP3 inflammasome activation in myeloid-derived cells. These findings may lead to therapeutic strategies aimed at halting the progression of liver injury and fibrogenesis in various liver pathogeneses driven by NLRP3 activation. (HEPATOLOGY 2018;67:736-749) SEE EDITORIAL ON PAGE 479
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I nflammation in the absence of infection (sterile inflammation; SI) has evolved as an important mechanism of liver injury in various acute and chronic liver disorders. (1, 2) SI in the liver is often initiated when damaged hepatocytes, undergoing cell death, expose intracellular molecules that can be recognized by cells of the innate immune system. In particular, resident macrophages or Kupffer cells become Abbreviations: a-SMA, alpha smooth muscle actin; ALD, alcoholic liver disease; CTGF, connective tissue growth factor; CXCL, chemokine (C-X-C motif) ligand; F4/80, murine macrophage marker; FISH, luorescence in situ hybridization; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; H&E, hematoxylin-eosin; HRP, horseradish peroxidase; HSC, hepatic stellate cell; IHC, immunohistochemistry; IL, interleukin; iNOS, inducible form of nitric oxide synthase; LF, liver fibrosis; LPS, lipopolysaccharide; Ly6-c, lymphocyte antigen 6 complex; MCP-1, monocyte chemoattractant protein-1; MPO, myeloperoxidase; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PBS, phosphate-buffered saline; SI, sterile inflammation; TIMP-1, tissue inhibitor of matrix metalloproteinase 1; TNF, tumor necrosis factor. activated and trigger an inflammatory response through common pathways involving the NLRP3 inflammasome and interleukin-1 beta (IL-1b). (3, 4) Activation of the NLRP3 inflammasome results in a wide range of immune responses, including production of proinflammatory cytokines, chemokines with the subsequent recruitment of neutrophils and other immune cells, and cell death. (5, 6) Growing evidence has linked inflammasome-driven inflammation to tissue damage and liver fibrosis (LF) in conditions such as drug-induced liver injury, alcoholic steatohepatitis, and nonalcoholic steatohepatitis (NASH). (7) (8) (9) Recent studies from our lab using constitutively activated Nlrp3 mutant mice demonstrated that NLRP3 activation is not only required for hepatic inflammation and fibrosis, but is also sufficient to induce programmed inflammatory cell death termed pyroptosis. (10) The present study was conducted to dissect the downstream signals involved in this process and, in particular, to test the hypothesis that two pathways with growing importance in liver pathology, interleukin-17 (IL-17) (11) (12) (13) (14) (15) (16) (17) and tumor necrosis factor (TNF), (18) (19) (20) are key in amplifying and perpetuating the liver damage and fibrosis resulting from NLRP3 activation. We approached this hypothesis by breeding unique mouse models that express mutant hyperactive Nlrp3 in myeloid-derived cells in mice that are deficient in IL-17 or TNF and investigate liver inflammation and fibrogenesis in these mice.
Materials and Methods

MOUSE STRAINS
Nlrp3
A350VneoR mice were generated as described, with an alanine 350 to valine (A350V) substitution and the presence of an intronic floxed neomycin resistance cassette, in which expression of the mutation does not occur unless the Nlrp3 mutants are first bred with mice expressing Cre recombinase. (21) ) mice purchased from The Jackson Laboratory (Bar Harbor, ME)-background. The resultant mice were further crossed with il17a or Tnf knockout mice expressing a Cre recombinase under the Lysozyme promoter allowing for mutant Nlrp3 expression in myeloid-derived cells in mice deficient in il17a or Tnf. (22) Hemozygous Nlrp3 knockout littermates lacking the Cre recombinase were used as control animals. The experimental protocols were approved by the Institutional Animal Care and Use Committee at the University of California-San Diego. All efforts were made to minimize pain and distress during animal husbandry and experimental assessments.
IN VIVO LIPOPOLYSACCHARIDE INDUCTION
, and Nlrp3
A350V
Tnf 2/2 mice were given a single intraperitoneal injection of lipopolysaccharides (LPSs) from Escherichia coli 0127:B8 (Sigma-Aldrich, St. Louis, MO). LPS was injected at a concentration of 25 lg/kg, and mice were killed and liver was collected 4 hours postinjection.
LIVER SAMPLE PREPARATION
At an age of 7-9 days, pups were sacrificed, the peritoneal and thoracic cavities opened, and blood samples were taken by cardiac puncture. Next, using phosphate-buffered saline (PBS), blood was flushed out of the liver by a catheter in the left main cardiac chamber. Livers were harvested and tissue was divided: (1) a representative section was fixed in 10% formalin for 24 hours and embedded in paraffin; (2) samples of 50 mg were placed in 500 mL of RNAlater Solution (Life Technologies, Carlsbad, CA); and 
HISTOLOGY, IMMUNOHISTOCHEMISTRY, AND SIRIUS RED STAINING
Liver tissues were fixed, embedded in paraffin, and processed on slides for hematoxylin-eosin (H&E) staining. Inflammation was quantified on the basis of the nonalcoholic fatty liver disease (NAFLD) activity score by an experienced pathologist (Dr. Bettina Papouchado) in routinely stained tissue sections. (23) LF was assessed using Sirius Red, whereby liver sections were incubated for 2 hours at room temperature with an aqueous solution of saturated picric acid containing 0.1% Fast Green FCF and 0.1% Direct Red.
Primary monoclonal antibodies used to perform immunostaining were: anti-F4/80 (a murine panmacrophage marker; AbDSerotec, Hercules, CA); antimyeloperoxidase (MPO; Thermo Scientific, Waltham, MA); and anti-Ly6C (Abcam, Cambridge, UK); negative controls had primary antibodies omitted. Specimens were deparaffinized and hydrated in ethanol, and antigens were retrieved in citrate buffer (pH 6.0) for 30 minutes at 95 8C or treated with 2% bovine serum albumin 1 3 Triton in Tris-buffered saline/0.1% Tween 20 for 30 minutes at room temperature. Following overnight incubation with primary antibodies, horseradish peroxidase (HRP) or Alexa Fluor 488-conjugated second antibody was applied. For color reaction of HRP, streptavidin-peroxidase complex 3,3'-diaminobenzidine tetrahydroxychloride was used as chromogen, and the slides were counterstained with hematoxylin. All photos were taken by the NanoZoomer 2.0HT Slide Scanning System (Hamamatsu Photonics K.K., Hamamatsu, Japan). A total of three fields per sample were examined. The number of MPO-positive cells as well as the F4/80-stained area per field were determined using ImageJ software (National Institutes of Health, Bethesda, MD; Supporting Fig. S4 ).
FLUORESCENCE IN SITU HYBRIDIZATION
After deparaffinization and rehydration, specimens were permeabilized with PBS-0, 3% Triton for 30 minutes and then incubated at 728C for 2 minutes. Following incubation overnight at 628C with either TNF or IL-17A probe, slides were washed with hybridization buffer and mounted.
REAL-TIME PCR
Total RNA was isolated from liver tissue and analyzed as described. (10) Sequences of the primers used for quantitative PCR are given in Supporting  Table S1 .
IMMUNOBLOTTING ANALYSIS AND ENZYME-LINKED IMMUNOSORBENT ASSAY
Immunoblotting analysis was performed as described. (24) Anti-IL-17A antibody (Cell Signaling Technology, Danvers, MA), anti-TNF-a (Abcam), and anti-a-SMA (alpha smooth muscle actin; GeneTex, Irvine, CA) antibodies were used in combination with appropriate peroxidase-conjugated secondary antibodies. Protein load was verified with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (Genetex) or a-tubulin antibody (dilution 1:10,000; Hybridomabank, University of Iowa [kindly provided by M. Kaulich, University of California-San Diego, La Jolla, CA]). Bands were visualized with the enhanced chemiluminescence reagent and digitized using a charge-coupled device camera (ChemiDoc; Bio-Rad, Hercules, CA). Expression intensity was quantified by ImageLab (Bio-Rad). Quantification of serum IL-1b levels were performed according to the manufacturer's instruction (R&D Systems, Minneapolis, MN).
Unless stated otherwise, all other chemicals were purchased from Sigma-Aldrich.
FLUORESCENCE-ACTIVATED CELL SORTING ANALYSIS
Whole livers were force filtered through a 70-mm nylon cell strainer (BD Biosciences, Franklin Lakes, NJ) with PBS. The solution was centrifuged for 1 minute at 8˚C with 500 rpm, producing a pellet of parenchymal cells and a supernatant incorporating infiltrating cells. Infiltrating cells were classified by multicolor analysis after incubation with CD11b (eBioscience, San Diego, CA), F4/80 (AbD serotec, Kidlington, UK) and Ly6G (eBioscience) for 30 minutes on ice and washed with 3% fetal bovine serum/PBS. For analysis of intracellular production of TNF and IL17A, cells were further permeabilized and incubated with TNF (eBioscience) or IL17 (eBiosicence) antibodies. Cells were analyzed by flow cytometry (BD LRS II; BD Biosciences).
STATISTICAL ANALYSES
Analyses were performed with GraphPad software (version 5.03; GraphPad Software Inc., La Jolla, CA). Significance level was set at a 5 5% for all comparisons. Data were evaluated using the Kruskall . Unless otherwise stated, data are expressed as mean 6 SEM or as absolute number or percentage for categorical variables. Nlrp3  A350V MICE IS ASSOCIATED  WITH INCREASE IN TNF  AND IL-17 Mice expressing the Nlrp3 A350V mutation under the control of the lysozyme promoter exhibited severe liver inflammation (Fig. 1A) . Further histological analysis and immunohistochemical (IHC) staining revealed an increase in neutrophils staining positive for MPO (Fig.  1C) . In addition, livers of Nlrp3 A350V mice displayed elevated numbers of macrophages, with activated inflammatory macrophages being the dominant additional cell type, evidenced by high expression of F4/80 and Ly6C (Fig. 1C) . Because TNF and IL-17 are both known to be increased in several models of liver injury and have been increasingly linked to liver inflammation and fibrogenesis, (11, 20) we next assessed their levels in livers of Nlrp3 A350V mice. Interestingly, mRNA levels of Tnf in the liver of Nlrp3 A350V mice were increased 10-fold when compared to nonmutant littermates. Hepatic mRNA levels of Il17a were also significantly increased (5-fold; P < 0.05) in Nlrp3 A350V mice when compared to control animals (Fig. 1B) . In line with these changes, protein levels of TNF, the nonbiologically active monomerized form (17 kDa) as well as the biologically active homotrimer (52 kDa) (25) were significantly increased in livers of Nlrp3 mutant mice (4-fold; P < 0.05; Fig. 1D ). Protein levels of IL-17A were also found to be increased in Nlrp3 A350V mice when compared to controls (3-fold; P < 0.05; Fig. 1D ). Fluorescence in situ hybridization (FISH) staining showed a strong expression of TNF in portal track infiltration sites and IL17A in inflammatory foci (Fig. 1H) , indicating that infiltrating cells are the main source responsible for the production of these cytokines. Flow cytometry analysis revealed that Nlrp3 A350V mice have increase TNF-producing CD11b 
Results
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Ly6G
-cells (2-fold; P < 0.01) as well as TNF-producing CD11b (Fig. 1G) . We also investigated whether other proinflammatory and profibrotic cytokines or chemokines were also up-regulated in Nlrp3 A350V mice. Increased hepatic mRNA levels of IL-1b (5-fold; P < 0.05), IL-33 (3-fold; P < 0.05), as well as monocyte chemoattractant protein-1 (MCP-1; 4-fold; P < 0.05) were observed in mutant mice when compared to controls, whereas no change was found in mRNA levels of IL-6 and IL-18 (Fig. 1E ). Nlrp3 A350V mice showed increased protein levels of mature IL-1b and IL18 as measured by western blotting (Fig. 1F) .
TNF, BUT NOT IL-17, AMELIORATES Nlrp3-DEPENDENT LIVER INFLAMMATION
Based on increased levels of TNF and IL-17A in livers of Nlrp3 A350V mice, we next sought to investigate their role on the liver phenotype resulting from NLRP3 activation. Therefore, we crossed our Nlrp3 A350V mice with mice globally deficient for Tnf or Il17a, generating mice that exhibit mutant Nlrp3 expression in myeloid-derived cells, but were globally deficient in Il17a or Tnf. We included 7 animals per group and killed them at day 9 of age (Supporting Table S2 ). Control mice exhibited an average body weight of 4.4 g (range, 3.4-5.2), whereas Nlrp3 A350V mice were significantly smaller (1.8 g; range, 1.6-2.2). Nlrp3 mutant mice deficient for il17a also showed a reduced body weight when compared to il17a knockout mice, whereas Nlrp3 mutant mice deficient for Tnf were indistinguishable from Tnf knockout mice (Supporting Table S2 ). Analysis of liver weight revealed a significant increase in liver weight per body weight in Nlrp3 A350V mice when compared to control mice (Supporting Table S2 ; Fig. 2B ). This increase was also documented in Nlrp3
A350V
Il17a
2/2 mice when compared to Il17a -/-mice, whereas liver to body weight ratio was similar in Nlrp3 A350V Tnf 2/2 and Tnf -/-mice (Supporting Table S2 ; Fig. 2B ).
FIG. 1.
Evidence of IL17 and TNF in Nlrp3 mutant mice. Nlrp3 A350V mice exhibited severe liver inflammation (A). mRNA levels of TNF and IL-17 were increased in Nlrp3 A350V mice when compared to control mice (B). Detection of MPO (neutrophils), F4/80 (murine pan-macrophage marker), as well as Ly6C-positive (activated macrophages) cells in liver of Nlrp3 A350V mice (C). Protein levels of TNF monomer (17 kDa), trimeric TNF (52 kDa), and IL-17A were increased in liver samples of Nlrp3 A350V mice when compared to control mice (D). MCP-1, IL-33, as well as IL-1b mRNA levels were up-regulated in Nlrp3 A350V mice when compared to control mice, whereas IL-6 and IL-18 mRNA levels were similar between both groups (E). Mature IL-1b (17 kDa) as well as mature IL-18 (18 kDa), but not pro-IL1b (35 kDa) or pro-IL18 (24 kDa), protein levels were increased in liver samples of Nlrp3 A350V mice when compared to control mice (F). Flow cytometry analysis showed that Nlrp3 A350V mice have increase TNF-producing CD11b 1 Ly6G -cells as well as TNF-producing CD11b 
Ly6G
1 cells compared to controls (G). FISH staining showed a strong expression of TNF in portal track infiltration sites and IL17A in inflammatory foci (H). (*P < 0.05; **P < 0.01; ***P < 0.001). Fig. 2A,C) . Analysis of serum IL-1b levels revealed a significant increase in Nlrp3 A350V mice when compared to control mice (Fig.  2D) . Increased serum IL-1b levels were also present in Nlrp3 A350V Il17a 2/2 mice when compared to Il17a 2/2 mice, whereas levels in Nlrp3 A350V Tnf 2/2 and Tnf 2/2 mice were significantly reduced when compared to Nlrp3 A350V mice (Fig. 2D) .
INFILTRATION WITH NEUTROPHILS AND INFLAMMATORY MACROPHAGES IN Nlrp3 MUTANT MICE DEPENDS ON TNF SIGNALING
Because hepatic infiltration with neutrophils and inflammatory macrophages are prominent in Nlrp3 A350V mice, we next investigated these events in the combined knock-in knockout mice. IHC of liver sections showed higher numbers of MPO-positive cells in Nlrp3
A350V when compared to control mice. Nlrp3
A350V
Il17a
2/2 livers exhibited significantly fewer amounts of MPO cells whereas the number of positive cells in Nlrp3 A350V TNF 2/2 mice was not different from TNF 2/2 mice (Fig. 3A,B ). In line with this, mRNA levels of MPO were increased by 20-fold in Nlrp3 A350V mice when compared to control mice; levels in Nlrp3 A350V Il17a 2/2 mice were still increased 5-fold, and levels in Nlrp3 A350V Tnf 2/2 mice were not increased (Fig. 3B) . Because neutrophilic infiltration, as a consequence of NLRP3 activation, is mediated, in part, by a chemokine gradient, (26) we next quantified mRNA levels of chemokine (C-X-C motif) ligand (CXCL) 1 and CXCL2, two key chemokines involved in this process in livers of mice from the various experimental groups. We found a marked increase in Nlrp3 A350V mice (20-fold for CXCL1 and 30-fold for CXCL2) when compared to control animals (Fig. 4C) . This increase was also present in Nlrp3 A350V Il17a
2/2 mice (10-fold for CXCL1 and CXCL2). A significant decrease of CXCL1 and CXCL2 expression was observed in Nlrp3 A350V Tnf 2/2 mice when compared to Nlrp3 A350V mice (Fig. 4C) . Interestingly, pro-IL-1b mRNA levels were still up-regulated in both Nlrp3 A350V Tnf 2/2 mice (3-fold) and Nlrp3 A350V Il17a 2/2 mice (3-fold) compared to control mice ( Fig   3D) , whereas all groups of mice displayed similar IL-6 ( Fig. 3E) , IL-33 (Fig. 3F) , and pro-IL18 (Fig. 3G ) mRNA levels. However, protein levels of pro-IL1b and pro-IL18 as well as mature IL-1b and IL-18 were higher only in Nlrp3 A350V Il17a
2/2
, but not in Nlrp3 A350V Tnf 2/2 mice (Fig. 3H) . Analysis of hepatic macrophages by IHC revealed increased areas of F4/80 and levels of F4/80 mRNA in Nlrp3 A350V mice (6-fold; P < 0.05) when compared to control animals and unchanged levels in all other groups of mice (Fig. 4A,B) (Fig. 4C) . Surprisingly, CD68 mRNA levels were up-regulated only in Nlrp3 A350V Il17a 2/2 mice, but not in Nlrp3 A350V or Nlrp3 A350V Tnf 2/2 mice (Fig.  4D) . Further supporting the proinflammatory phenotype of macrophages in livers of Nlrp3 A350V mice and Nlrp3 A350V Il17a 2/2 mice, mRNA levels of iNOS (inducible form of nitric oxide synthase) and TNF were found to be increased in both groups. iNOS mRNA levels were found unchanged in Nlrp3 A350V TNF 2/2 mice (Fig. 4E,F) .
TNF, BUT NOT IL-17, PREVENTS HEPATIC STELLATE CELL ACTIVATION IN Nlrp3 MUTANT MICE
Liver inflammation and chronic infiltration with inflammatory macrophages is closely correlated to activation of hepatic stellate cells (HSCs) and development of LF. (27) Liver sections were therefore stained with Sirius Red to assess collagen deposition (Fig. 5A) . As expected, positive Sirius Red staining was detectable in liver sections of control mice, Il17a 2/2 mice, and Tnf -/-mice only in close proximity of the portal field (Fig. 5A) . Liver sections of Nlrp3 A350V and Nlrp3 A350V Il17a 2/2 mice exhibited bridging fibrosis, whereas liver sections of Nlrp3 A350V Tnf 2/2 mice did not show increased collagen deposition. mRNA levels of connective tissue growth factor (ctgf; Fig. 5B ), tissue inhibitor of matrix metalloproteinase 1 (timp1; Fig.  5C ), and a-SMA (Fig. 5D) (A,B) . mRNA levels of MPO were increased Nlrp3 A350V and Nlrp3 A350V IL-17 2/2 mice, but not elevated in Nlrp3 A350V TNF 2/2 mice (B). Because neutrophilic migration is mediated by chemokine ligands, we quantified mRNA levels of CXCL1 and CXCL2 in livers. We found a marked increase of these chemokines in Nlrp3 A350V mice (20-fold for CXCL1 and 30-fold for CXCL2) when compared to control mice (C). This increase was also present in Nlrp3 A350V IL-17 2/2 mice (10-fold for CXCL1 and CXCL2) (C). pro-IL-1b mRNA levels were up-regulated in both Nlrp3 A350V TNF 2/2 mice and Nlrp3 A350V IL-17 2/2 mice compared to control mice (D), whereas all groups of mice displayed similar IL-6 (E), IL-33 (F) and pro-IL18 mRNA levels (G). However, protein levels of proIL1b and pro-IL18 as well as mature IL-1b and IL-18 were higher only in Nlrp3 mice (H). (*P < 0.05; **P < 0.01; ***P < 0.001).
FIG. 4. Macrophages infiltration and polarization in combined Nlrp3
A350V knock-in and IL-17 2/2 , TNF 2/2 mice. Hepatic macrophages, when assessed by IHC or mRNA levels for F4/80, were increased in Nlrp3 A350V mice and unchanged in all other groups of mice (A,B). Ly6-c mRNA levels were increased in Nlrp3 A350V mice and Nlrp3 mice, when compared to control mice (C). Surprisingly, CD68 mRNA levels were increased in Nlrp3 A350V IL-17 2/2 mice compared to Nlrp3 A350V , even though similar levels were found between mutant and control mice (D). The inflammatory phenotype of infiltrating macrophages in Nlrp3 A350V mice and Nlrp3 A350V IL-17 2/2 mice as measured by mRNA levels of iNOS and TNF were found to be increased (E,F). (*P < 0.05; **P < 0.01). , whereas control mice, IL-17 2/2 , TNF 2/2 , and Nlrp3 A350V TNF 2/2 only presented collagen deposition in close proximity to the portal fields (A). Markers for HSC activation (CTGF, TIMP1, and a-SMA) were increased in Nlrp3 A350V and Nlrp3 A350V IL-17 2/2 mice when compared to control mice, whereas aforementioned markers were not increased in Nlrp3 A350V TNF 2/2 mice when compared to TNF 2/2 mice (B-D). Protein levels of a-SMA were also increased in Nlrp3 A350V and Nlrp3 A350V IL-17 2/2 mice when compared to their corresponding control animals, with no difference in Nlrp3 A350V TNF 2/2 and TNF 2/2 mice (E). Summary of the role of TNF and IL-17 pathways in Nlrp3-driven liver damage (F). (*P < 0.05; **P < 0.01; ***P < 0.001). (Fig. 5E ).
LPS-DRIVEN LIVER DAMAGE IS AMELIORATED BY TNF, BUT NOT IL17, IN Nlrp3 MUTANT MICE
In order to further evaluate the involvement of TNF and IL17 in NLRP3-mediated liver damage, we challenged the different groups of mice with an inflammatory stimulus. We injected LPS intraperitoneally and observed the liver damage after 4 hours. Liver histology revealed strong inflammation in Nlrp3 A350V mice (grade 2) as well as Nlrp3 A350V Il17a 2/2 mice (grade 3), whereas Nlrp3 A350V Tnf 2/2 mice showed no signs of inflammatory changes (grade 0; Fig. 6A,B) . IHC of liver sections displayed extensive MPO-positive cells infiltration (Fig. 6A,C) along with the presence of a high number of F4/80 macrophages (Fig. 6A,D . Liver sections of Nlrp3 A350V Tnf 2/2 mice displayed fewer numbers of MPO-infiltrating positive cells (Fig. 6A,C) as well as a decreased amount of F4/80-positive cells (Fig. 6A,D) .
Discussion
The key findings of the present study provide information about the downstream pathways involved in the development of liver inflammation and fibrogenesis associated with myeloid-cell-specific NLRP3 activation. Our results demonstrate that the levels of both TNF and IL-17, two key cytokines linked to liver pathology, are increased in livers of mice with constitutively activated Nlrp3 in myeloid-derived cells. TNF signaling, but not IL-17, appears to be crucial in triggering liver inflammation, neutrophils, and proinflammatory macrophage recruitment, as well as in activation of fibrogenic pathways that are central to the development of LF.
Emerging evidence supports a central role of NLRP3 inflammasome in the pathogenesis of many liver diseases, including alcoholic liver disease (ALD) and NAFLD as well as LF. (24, (28) (29) (30) (31) Indeed, studies using global knockout mice of different inflammasome components, or pharmacological inhibitors of IL-1b signaling, have suggested protective effects of NLRP3 signaling suppression in liver injury and fibrotic changes associated with these conditions. (28) IL-1b signaling appears to be an important contributor for the liver changes resulting from NLRP3 activation. However, our previous results indicate that IL-1-independent pathways also play an important role given that treatment with an IL-1 receptor antagonist (anakinra) only partially attenuated liver inflammation, whereas fibrogenesis was unchanged. (10) Additionally, deletion of the IL-18 receptor in Nlrp3 knockin mice resulted in partial phenotypic rescue that abolished skin and visceral disease in young mice and normalized serum cytokines to a greater extent than breeding to IL-1 receptor knockout mice. (32) Significant systemic inflammation developed in aging Nlrp3 mutant IL-18 receptor knockout mice, suggesting that IL-1b and IL-18 drive pathology at different stages of the disease process. (32) The current study was conducted to further dissect the downstream events that may amplify and perpetuate the inflammatory responses and contribute to activation of HSCs, a central event in LF. (33) We focused on IL-17 and TNF, two pathways that have been increasingly linked to liver injury, particular in the context of NAFLD and ALD. Although IL-17 production can be regulated by NLRP3 activation, (34) (35) (36) TNF production is mainly thought to occur through signals that lead to activation of nuclear factor kappa B. (37, 38) NLRP3 activation may amplify this production in an autocrine or paracrine fashion by inducing the maturation and release of IL-1b and IL-18, which then interact with their own membrane receptors. (39, 40) Furthermore, both cytokines have been involved in creating an autoinflammatory loop that characterizes these disorders, (41) whereas IL-17 is an important contributor for tissue recruitment of neutrophils, a central feature found in livers of mice with constitutive active NLRP3.
Our results demonstrate that NLRP3 inflammasomeinduced liver inflammation and liver fibrogenesis are influenced by IL-17 and TNF, with TNF having a more prominent effect (Fig. 5F ). Expression of both cytokines was increased in livers of Nlrp3 mutant mice. Studies using FISH and fluorescence-activated cell sorting analysis demonstrated that infiltrating inflammatory cells are the main source for these cytokines. The unexpected significance of TNF ablation in Nlrp3 mutant mice could be explained by a feedback loop with IL-1b as reported by Tangi et al. The investigators showed an increase in IL-1b mRNA and protein levels in cell-culture supernatants of aortic smooth muscle cells upon stimulation with TNF that was dependent on NLRP3 signaling. (42) Consistent with this, our current data demonstrate a significant reduction of IL-1b levels in Nlrp3 mutants in the absence of TNF. Because of the important role for IL-17 in recruitment of neutrophils to the liver and its role in the context of LF and activation of HSCs, we expected a major beneficial effect of IL-17 ablation on liver disease in our Nlrp3 gain-of-function model. (14, 16) Surprisingly, we observed only a slight reduction in neutrophilic infiltration by IL-17 ablation. These findings suggest that the inflammatory environment generated by NLRP3 activation and the recruitment of circulating neutrophils occur by parallel redundant pathways, which may explain the only minimal protective effects on the development of LF observed in our mutant mice.
Although the role of TNF and its inhibition in animal models of liver injury offered encouraging therapeutic perspectives, targeting this cytokine for the treatment of human liver diseases remains uncertain. (43) Indeed, extensive evidence from animal models on various liver disorders, such nonalcoholic liver disease and ALD have demonstrated a central role for TNF in development of liver injury and modulation of disease severity. Treatment of leptin-deficient ob/ob mice with anti-TNF antibodies improves NASH and hepatic insulin resistance. (44) Mice genetically deficient in TNF type 1 receptor are resistant to steatosis and liver injury induced by high-caloric diets as well as alcohol exposure. (45) (46) (47) Our current results also suggest the potential beneficial effects of modulating TNF signaling in the context of NLRP3-driven liver pathology. In humans, various molecules that target TNF such as pentoxifylline, etanercept, (a fusion protein that acts as a "decoy receptor" for TNF), as well as the various anti-TNF monoclonal antibodies currently available for clinical use, have been proposed as potential therapy for the treatment of liver disease. Early studies using pentoxifylline, a weak TNF inhibitor, have shown positive results with diminished serum levels of aminotransferases and improved inflammation and fibrosis in patients with NASH. (48) However, caution must be taken because a randomized, placebo-controlled trial using etanercept was associated with a significantly higher mortality rate in patients with moderate-to-severe acute alcoholic hepatitis, an effect that was mainly attributed to an increased rate of severe infections. (49) In summary, our current study reveals key roles for TNF and, to a lesser extent, IL-17 as mediators of liver inflammation and fibrosis induced by constitutive NLRP3 inflammasome activation in myeloid derived cells. These findings may lead to therapeutic strategies aimed at halting the progression of liver injury and fibrogenesis in various liver pathologies driven by NLRP3 activation.
